Tyco to scoop up C.R. Bard

Article

Another medical device manufacturer may soon join Tyco International. The multinational company, which has made a habit of gobbling up others, has signed a definitive agreement to buy C.R. Bard in a stock swap valued at about $3.2 billion, including the

Another medical device manufacturer may soon join Tyco International. The multinational company, which has made a habit of gobbling up others, has signed a definitive agreement to buy C.R. Bard in a stock swap valued at about $3.2 billion, including the assumption of net debt, based on Tyco’s May 29 closing share price of $57. Bard shareholders will receive Tyco shares valued (just prior to the Bard shareholder vote) at $60 for each share of Bard, subject to an adjustment should Tyco stock trade below $50 during a measurement period. Bard, which had 2000 revenues of $1.1 billion, is a leading medical devices manufacturer of products used for vascular, urological, and oncological diagnosis and intervention as well as surgical specialties. Tyco’s holdings include US Surgical and Mallinckrodt.

Newsletter

Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.

Recent Videos
Reducing Mammography Workload by Nearly 40 Percent? What a New Hybrid AI Study Reveals
 What New Research Reveals About Portable Low-Field MRI and Patients with Suspected Alzheimer’s Disease
Diagnostic Imaging's Weekly Scan: August 11 — August 17 (Video Version)
© 2025 MJH Life Sciences

All rights reserved.